New antibody combo tackles solid tumors in early trial
NCT ID NCT06391775
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This early-phase trial tested a new antibody drug, GEN1055, in 21 adults with advanced solid tumors. The goal was to check safety and find the right dose when used alone or with pembrolizumab (with or without chemotherapy). The study was stopped early, but results help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Hospital Universtari Val D´Hebron
Barcelona, Spain
-
Start Madrid Ciocc Hm Sanchinarro
Madrid, Spain
-
Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear acupressure: a new weapon against chemotherapy side effects?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
- Can a new tracer light up tumors better than standard PET scans?
- Personalized weight loss coaching could help cancer survivors shed pounds
- Healthy volunteers needed to test new version of cancer drug
- New PET tracer aims to light up tumors, but trial stalls